About Qubis
Qubis, an accelerator and incubator program founded in 1984, is based in Belfast, United Kingdom. With a presence in 2 countries, it has supported around 46 startups in sectors like Life Sciences, Enterprise Applications. As of Oct 2026, Qubis has witnessed 8 portfolio exits. Most notable companies in
its portfolio include Cirdan Imaging, Kainos and Cibus. The program is backed by a team of 13 people who primarily support Seed startups based in United Kingdom. Its latest investment was a $1.75M Seed round in AMPLY Discovery on May 01, 2025, which also saw participation from Twin Path Ventures and Venture Science.
Key Metrics
Founded Year
1984
Location
Belfast, United Kingdom
Portfolio Companies
Sectors of Investment
Stages of Investment
Seed, PE & 3 more
Locations of Investment
Qubis' List of Top Investments
Qubis has a portfolio of 46 companies. Their most notable investments are in AMPLY Discovery and VascVersa.Their portfolio spans across United Kingdom and United States. They have invested in Life Sciences, Enterprise Applications, High Tech and 13 other sectors, across stages such as Seed, PE and 3 more. Here is the list of top investments by Qubis:Cirdan Imaging designs manufactures and supplies medical imaging & informatics technology for the medical diagnosis and treatment of cancer. The company offers VividPath, a PACS image acquisition and viewer workstation to acquire, view, annotate, report, and store images in a database. Also provides gross specimen macro imaging systems for pathology laboratories; digital microscope cameras to support live onscreen review and image capture of slides; and medical imaging software solutions. The company has additional offices in Canada and Australia and offers products through a network of distributors in Europe, the Middle East, and Africa.
Key facts about Cirdan Imaging
- Founded Year: 2010
- Location: Lisburn (United Kingdom)
- Annual Revenue: £1M - £10M as on Jun 30, 2019
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $27.6M
- Employee Count: 121 as on Aug 31, 2026
- Investors: Salica Investments, 57 Stars and 41 Others
- Latest Funding Round: Venture Debt, Apr 14, 2026, $*****
- Highlight: Editors' Pick
2. Kainos
Provider of digital transformation services and software implementation consulting support. Services include the development of digital platforms to facilitate organizational growth and operational change. Consulting teams manage the integration and optimization of enterprise resource planning software to meet business requirements. Additional capabilities involve the application of artificial intelligence and natural language processing to automate document analysis and data extraction tasks. Technical staff support the design and deployment of digital tools intended to streamline internal workflows and processes.
Key facts about Kainos
- Founded Year: 1986
- Location: Belfast (United Kingdom)
- Stage: Public
- Employee Count: 3,510 as on Aug 31, 2026
- Investors: Herald Investment Management, Qubis and 1 Other
- Highlight: Public

3. Cibus
Developer of precision breeding technologies for resilient and vigorous crops. The company focuses on creating crops with specific traits to withstand environmental stressors. It works with agricultural partners to develop seeds resistant to heat, pests, fungus, and weeds. The goal is to produce crops that require fewer chemicals and less energy.
Key facts about Cibus
- Founded Year: 2001
- Location: San Diego (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $34.5M
- Employee Count: 320 as on Aug 31, 2026
- Investors: Fidelity Investments, Acks and 7 Others
- Latest Funding Round: Post IPO, Apr 08, 2020, $*****
- Highlight: Public

4. Nuada
Provider of carbon capture technology solutions. It uses energy-efficient filtration machines that make carbon capture commercially viable and pave the path for zero carbon emissions in industry. It utilizes solid sorbent materials and operates via vacuum swing adsorption gas separation technology.
Key facts about Nuada
- Founded Year: 2012
- Location: Newtownabbey (United Kingdom)
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $12.8M
- Employee Count: 67 as on Aug 31, 2026
- Investors: NetScientific, EIC Fund and 22 Others
- Latest Funding Round: Grant (prize money), Apr 08, 2025, $*****
- Highlight: Editors' Pick
Developer of drug delivery platform for ophthalmic diseases. The company platform is meant for chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma. It offers a flagship product EyeLief, is a photo cross-linked sustained-release biodegradable implant delivering both biologic and small molecule drugs .
Key facts about Re-Vana Therapeutics
- Founded Year: 2015
- Location: Belfast (United Kingdom)
- Stage: Series A
- Total Funding till date: $20M
- Employee Count: 24 as on Aug 31, 2026
- Investors: Exsight Ventures, Qubis and 11 Others
- Latest Funding Round: Series A, Feb 06, 2026, $*****
- Highlight: Editors' Pick
Qubis' Year-on-Year Investment Trends
Qubis has invested in 47 companies over the last 20 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 4 investments. Its most recent first time investment was in StimOxyGen and most recent follow-on round was in AMPLY Discovery.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 3 | 1 | 4 |
2024 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
2022 | 5 | 4 | 9 |
2021 | 3 | 0 | 3 |
2020 | 3 | 0 | 3 |
2019 | 0 | 0 | 0 |
2018 | 2 | 0 | 2 |
Qubis' Investments by Stage
Qubis has made 18 investments in Seed stage with an average round size of $1.2M, 1 investment in PE stage with an average round size of $2.5M, 1 investment in Post IPO stage with an average round size of $702K, 1 investment in Series A stage with an average round size of $5.63M and 1 investment in Series B stage with an average round size of $15.2M.Stage of entry | No. of Investments |
|---|---|
Seed | 18 |
PE | 1 |
Post IPO | 1 |
Series A | 1 |
Series B | 1 |
Note: We have considered here, only first round of investments
Qubis' Investments by Sector
Qubis has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, High Tech and Food and Agriculture Tech. Notably, it has invested in 39 Enterprise (B2B) companies, 33 Tech companies, 16 Software companies and at least 8 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 14 |
Enterprise Applications | 7 |
HealthTech | 6 |
High Tech | 4 |
Food and Agriculture Tech | 3 |
Others | 11 |
Note: We have considered here, only first round of investments
Qubis' Investments by Geography
Qubis has made most investments in United Kingdom (21), followed by United States where it has made 1 investment.Country | No. of Investments |
|---|---|
United Kingdom | 21 |
United States | 1 |
Note: We have considered here, only first round of investments
Qubis' recent investments
Qubis has not made any investment in 2026 so far.Here are the most recent investments by Qubis:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 01, 2025 | United Kingdom | Seed | 6067 | [+3] | |
Mar 11, 2025 | United Kingdom | Seed | 1231 | [+1] | |
Feb 25, 2025 | United Kingdom | Seed | 3128 | [+3] | |
Jan 13, 2025 | United Kingdom | Seed | 6210 | ||
Jun 19, 2024 | United Kingdom | Seed | 6669 |
IPOs and Publicly Listed companies in Qubis' Portfolio
4 of Qubis' portfolio companies have become public. Fusion Antibodies got listed on the London Stock Exchange (LSE), in Dec 2017 at marketcap of $36.5M and Cibus got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of undefined.Here are Qubis' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 18, 2017 | Jul 26, 2007 | PE | 3745 | |
Jul 20, 2017 | Apr 08, 2020 | Post IPO | 1882 | |
Jul 10, 2015 | - | - | 4881 | |
- | - | - | 6912 |
Acquired companies in Qubis' Portfolio
4 companies from Qubis' portfolio have been acquired. The most recent acquisition was ProAxsis in Oct 2020 by NetScientific for $*****.Here are Qubis' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 16, 2020 | - | - | 2613 | |
Mar 03, 2020 | - | - | 5729 | |
Jun 21, 2016 | Apr 05, 2009 | Seed | 2943 | |
Oct 06, 2010 | Jul 20, 2006 | Series B | 2455 |
Team profile of Qubis
Qubis has a team of 13 members including 9 Partners and 1 Principal located in United Kingdom. Qubis' team sits on the board of 1 company.Here is a list of top team members in Qubis:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Belfast | - | ||
Partner | United Kingdom | - | ||
Partner | United Kingdom | - | ||
Partner | - | - | - | |
Partner | Belfast | - | - | |
Partner | United Kingdom | - | - | |
Partner | Belfast | - | - | |
Partner | Hillsborough | - | - | |
Partner | Belfast | - | ||
Principal | Manchester | - |
Co-investors of Qubis
Over the past 20 years, 94 investors have co-invested in Qubis's portfolio companies. This includes funds and angels.
- Invested before Qubis: Adama, Fidelity Investments and 11 others have invested in rounds before Qubis. There is 1 company where Adama has invested before Qubis and 1 company where Fidelity Investments has invested before Qubis.
- Top Co-investors of Qubis: 38 investors entered a company along with Qubis. These include investors like Invest Northern Ireland (6 companies).
- Invested after Qubis: A total of 43 investors have invested in Qubis's portfolio after their investments. Top Investors include Clarendon Fund Managers (4 companies) and British Business Bank (2 companies).
Recent News related to Qubis
•
•
Belfast's Amply Secures $1.75 Million for AI Drug DiscoveryStartup Rise EU•May 01, 2025•AMPLY Discovery, Twin Path Ventures, Venture Science, Clarendon Fund Managers and 2 others
•
•
Belfast’s Retinize secures £1.6m to ‘disrupt the animation space’Silicon Republic•Feb 25, 2025•RETìníZE, Qubis, Innovation Ulster, Sure Valley Ventures and 2 others
•
Dia Beta Labs secures £1.2m to advance breakthrough obesity and type 2 diabetes drugsUKBAA•Jan 13, 2025•Dia Beta Labs, Gov, Qubis, DSW Ventures
•
TraitSeq secures significant pre-seed investment to propel growthAgroPages•Jun 19, 2024•TraitSeq, Deeptech Seed Fund, Qubis
•
ChatGPT of molecular discovery: Amply raises £1.4M for AI-powered drug discoveryTech Funding News•Feb 12, 2024•AMPLY Discovery, Gov, Innosuisse, Co-Fund NI and 9 others
•
Northern Ireland-Based Cancer Dx Firm GenoMe Diagnostics Raises £1.4M360Dx•Mar 07, 2023•Genome Diagnostics, Gov, GenoME Diagnostics, Qubis and 3 others
•
Belfast-based GenoME raises £1.4 million to help with earlier detection of ovarian cancerTech.eu•Mar 03, 2023•GenoME Diagnostics, Qubis, Deepbridge Capital, Genome Medical and 2 others
•
Re-Vana Therapeutics Raises USD11.9M in Series A FundingFinSMEs•Nov 30, 2022•Re-Vana Therapeutics, Visionary Ventures, Exsight Ventures, InFocus Capital Partners and 4 others
